Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Thromb Res. 2016 Feb 1;140:110–117. doi: 10.1016/j.thromres.2016.01.026

Table 3.

Summary.

What is known on this topic

  • ASA is the primary antithrombotic drug for patients with cfVADs

  • Pathological shear stress is the primary activator of platelets in cfVADs

  • ASA efficacy has been studied under static, low, high and non-physiological flow conditions, however its efficacy under dynamic, device–related conditions is poorly understood.

What this paper adds

  • ASA has limited efficacy in modulating shear-mediated platelet activation under both constant and dynamic levels of elevated shear stress and overall shear stress accumulation experienced in cfVADs

  • ASA is unable to limit shear-mediated platelet sensitization, or continued activation after brief high shear stress exposure

  • A clear need exists for the development of strategies of agents able to modulate shear-mediated platelet activation associated with the “hypershear” levels (600–1000 dyns/cm2) associated with mechanical circulatory support devices such as cfVADs